Generics Worry Fed. Circ. Blew Up 'Routine' Labeling Practice
By Dani Kass · October 7, 2020, 2:35 PM EDT
The Federal Circuit's recent decision to revive a $235 million induced infringement verdict against Teva has left generic-drug makers scared that they'll be effectively barred from selling patent-protected drugs for approved,...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login